Introduction
============

Amlodipine is a dihydropyridine calcium channel blocker. It is used for management of hypertension and angina pectoris.[@b1-aci-6-2011-053] Several methods were developed for amlodipine determination. The most recent reported methods include capillary electrophoresis (CE) methods which were used for amlodipine determination[@b2-aci-6-2011-053]--[@b4-aci-6-2011-053] or for enantiomer separation and determination of amlodipine.[@b5-aci-6-2011-053]--[@b7-aci-6-2011-053]

HPLC methods were used for the determination of amoldipine alone either in human fluids or in tablet form.[@b8-aci-6-2011-053]--[@b15-aci-6-2011-053] Other HPLC methods determine amlodipine in a mixture with another drug as metoprolol succinate,[@b16-aci-6-2011-053],[@b17-aci-6-2011-053] atrovastatin,[@b18-aci-6-2011-053],[@b19-aci-6-2011-053] benazepril[@b20-aci-6-2011-053],[@b21-aci-6-2011-053] and losartan.[@b22-aci-6-2011-053] Amlodipine was determined in tablets and biological fluids using voltametric method.[@b23-aci-6-2011-053] Spectrophotometric methods were used for the determination of amlodipine,[@b24-aci-6-2011-053],[@b25-aci-6-2011-053] amlodipine, enalapril mixture[@b26-aci-6-2011-053] or for monitoring amlodipine photodegradation.[@b27-aci-6-2011-053]

Valsartan is an angiotensin II receptor antagonist used in the management of hypertension to reduce cardiovascular mortality in patients with left ventricular dysfunction following myocardial infarction and heart failure.[@b1-aci-6-2011-053]

Several methods have been reported for valsartan assay including HPLC methods,[@b28-aci-6-2011-053]--[@b32-aci-6-2011-053] spectrofluorimetric method[@b33-aci-6-2011-053] and capillary electrophoresis.[@b34-aci-6-2011-053]

Valsartan and hydrochlorothiazide mixture were determined using HPLC methods,[@b35-aci-6-2011-053]--[@b37-aci-6-2011-053] derivative spectrophotometric methods,[@b38-aci-6-2011-053]--[@b40-aci-6-2011-053] TLC method[@b41-aci-6-2011-053] and CE method.[@b42-aci-6-2011-053]

Two HPLC methods for the determination of valsartan and nebivolol were reported.[@b43-aci-6-2011-053],[@b44-aci-6-2011-053]

Simultaneous determination of valsartan and amlodipine in post mortem whole blood was carried out using HPLC-MS technique.[@b45-aci-6-2011-053]

The goal of antihypertensive therapy is to abolish the risks associated with blood pressure elevation without adversely affecting quality of life. Drug selection is based on efficacy in lowering blood pressure and in reducing cardiovascular end points including stroke, myocardial infarction and heart failure. The American Society of Hypertension presents a paper on combination therapy of hypertension. Specific combinations are designated as preferred or acceptable, less effective combinations are also identified. The study classifies the combination therapy of amlodipine and valsartan as acceptable.[@b46-aci-6-2011-053]

Experimental
============

Chemicals and reagents
----------------------

-   Amlodipine and valsartan donated by Novartis, Egypt.

-   Exforge tablets labeled to contain 10 mg of amlpdipine and 160 mg of valsartan. Batch number 0051, manufactured by Novartis, Egypt.

-   Methanol analytical grade (Analar).

Apparatus
---------

-   Ultraviolet / Visible spectrophotometer, Shimadzu, Japan 1601pc.

-   Ultrasonic crest model 575T Cortland, New York 13045, USA.

Sample Preparation
==================

Stock methanolic solution of amlodipine and valsartan of concentration 100 μg/ml and 200 μg/ml respectively were separately prepared by dissolving the appropriate amount of the respective substance in methanol. Working standard solutions used for method optimization were prepared freshly before application by mixing suitable aliquots of stock solutions of amlodipine and valsartan and diluted with methanol to obtain the required concentration ranges.

Stock methanolic solution of laboratory prepared mixture of amlodipine and valsartan containing 100 μg/ml and 1.6 mg/ml respectively was prepared by dissolving 25 mg amlodipine and 400 mg valsartan in 250 ml methanol.

Tablets working solution was prepared by dissolving an accurately weighed quantity of powdered exforge tablets sample containing an equivalent of 10 mg amlodipine and 160 mg valsartan was transferred into 100 ml volumetric flask, then 70 ml methanol was added. The mixture was sonicated for ten minutes and the volume was made up using methanol, then the sample was filtered.

Procedure
=========

Aliquots (1--8 ml) or (1--9 ml) of amlodipine or valsartan stock solutions respectively were transferred into two separate series of 10 ml volumetric flasks and volumes were made up with methanol. The absorbance spectrum of each flask were recorded at zero order between 200--450 nm and stored in a personal computer.

The absorbance of amlodipine series were determined in zero order at 360.5 nm.

The UV absorption spectra of the series of valsartan solutions were divided wavelength by wavelength by a standard spectrum of amlodipine (40 μg/ml). The first derivative of the obtained ratio spectra with Δλ = 4 nm and scaling factor equal 10 were used for determination of valsartan concentration from the amplitude at 290 nm.

Application of the Method for the Determination of Laboratory Prepared Mixture
==============================================================================

The method was applied for the determination of laboratory prepared mixture of amlodipine and valsartan containing 100 μg/ml and 1.6 mg/ml respectively. Aliquots (1--8 ml) and (1.5--10 ml) of the stock methanolic solution of laboratory prepared mixture were transferred into two separate series of 10 ml and 100 ml volumetric flasks, volumes were made up using methanol. The first series of (10 ml) volumetric flasks was used for the determination of amlodipine, while the other series (100 ml volumetric flasks) was used for the determination of valsartan applying the same mentioned procedure.

Application of the Method for the Determination of Exforge tablets
==================================================================

Aliquots of 1.5, 4 and 8 ml of tablets working solution were transferred into two separate series of 10 ml and 100 ml volumetric flasks for determination of amlodipine and valsartan respectively.

To study the accuracy of the proposed method and check the interference from excipients present in the dosage form, recovery experiment were carried out by standard addition method. This study was performed by addition of different amounts of amlodipine and valsartan to a known concentration of the commercial tablets.

Result and Discussion
=====================

The UV spectra of amlodipine and valsartan in zero order show that amlodipine has a significant peak at 360.5 nm at which the spectrum of valsartan does not interfere ([Fig. 2](#f2-aci-6-2011-053){ref-type="fig"}). So methanolic solution of amlodipine was quantitatively determined at 360.5 nm, Beer's law was obeyed over concentration range 10--80 μg/ml. The amlodipine concentration could be calculated using the following equation. $$A = 0.011C + 0.003$$

Valsartan spectrum in zero order shows a complete overlapping with that of amlodipine ([Fig. 2](#f2-aci-6-2011-053){ref-type="fig"}). Applying first, second and third order spectra did not resolve valsartan peaks. So first derivative of the ratio spectra was applied to determine valsartan in presence of amlodipine.

The influence of Δλ and the effect of the divisor concentration on the calibration graph for the proposed mixture was studied in order to select the best factor for the determination. Results indicate that Δλ = 4 was the most suitable one, while divisor concentration range 10--60 μg/ml gave good results, 40 μg/ml was used overall.

For the determination of valsartan the absorption spectra of valsartan was divided by that of standard amlodipine solution (40 μg/ml). The first derivative of the developed ratio spectra were calculated with Δλ = 4 and scaling factor equal 10. ([Fig. 3](#f3-aci-6-2011-053){ref-type="fig"}) shows that valsartan could be determined by measuring the amplitude at 290 nm.

The proposed method is applicable over the concentration range 20--180 μg/ml. Valsartan concentrations could be determined applying the following equation. $$A = 0.086C + 0.101$$

Parameters of regression equations of both drugs are collected in [Table 1](#t1-aci-6-2011-053){ref-type="table"}.

Accuracy of the method was tested and results show M ± SD of 100.19 ± 0.76 and 99.91 ± 0.55 for amlodipine and valsartan respectively, ([Table 2](#t2-aci-6-2011-053){ref-type="table"}).

In order to demonstrate the validity and applicability of the proposed method, recovery studies were performed by analysing laboratory prepared mixture of amlodipine and valsartan with different composition ratio ([Table 3](#t3-aci-6-2011-053){ref-type="table"}).

Results of the tested samples within day (repeatability) and between days (reproducibility) show standard deviation between results less than one indicating high degree of precision ([Tables 4](#t4-aci-6-2011-053){ref-type="table"} and [5](#t5-aci-6-2011-053){ref-type="table"}).

The proposed method can be conveniently used to determine both amlodipine and valsartan in exforge tablets ([Table 6](#t6-aci-6-2011-053){ref-type="table"}).

The validity of the method was assessed by applying the standard addition technique for the determination of exforge tablets, good results were obtained ([Table 7](#t7-aci-6-2011-053){ref-type="table"}).

Conclusion
==========

In this study a new spectrophotometric method was developed to identify amlodipine and valsartan in mixture without previous separation. The method was optimized and validated. The method was successfully applied for the determination of amlodipine and valsartan in exforge tablets.

This method can yield results in a short time and does not require relatively expensive apparatus like HPLC.
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###### 

Analytical parameters from calibration graph in quantification of amlodipine and valsartan by the proposed method.

  **Regression data**                   **Amlodipine**   **Valsartan**
  ------------------------------------- ---------------- ---------------
  Linearity                             10--80 μg/ml     20--180 μg/ml
  Slope                                 0.011            0.086
  Intercept                             0.003            0.101
  r (correlation coefficient)           0.9996           0.9997
  r^2^ (coefficient of determination)   0.999            0.999
  LOD (limit of detection)              5.5 μg/ml        8 μg/ml
  LOQ (limit of quantitation)           8.5 μg/ml        12 μg/ml

###### 

Results of quantitative analysis of amlodipine and valsartan in bulk powder by the proposed method.

  **Taken**   **Found**   **% recovery**                                  
  ----------- ----------- ---------------- --------------- -------------- --------
  10          20          10.09            20.01           100.90         100.55
  25          40          24.88            40.12           99.5           100.30
  45          80          45.16            79.32           100.35         99.15
  65          140         65.59            139.52          100.90         99.66
  75          180         74.48            179.84          99.30          99.88
              M ± SD                       100.19 ± 0.76   99.91 ± 0.55   

**Notes:**

Aml = amlodipine;

Val = valsartan.

###### 

Results of quantitative analysis of amlodipine and valsartan in laboratory prepared mixture by the proposed method.

  **Taken concentration of each drug in mixture**   **Found**   **% recovery**                             
  ------------------------------------------------- ----------- ---------------- -------- ---------------- ----------------
  15                                                24          14.90            23.89    99.33            99.55
  20                                                32          20.22            32.27    101.10           100.84
  40                                                64          39.94            64.64    99.85            101.00
  60                                                96          60.53            95.22    100.88           99.19
  80                                                128         79.55            129.16   99.44            100.90
                                                                M ± SD                    100.12 ± 0.820   100.30 ± 0.857

###### 

Results of quantitative analysis of amlodipine and valsartan in laboratory prepared mixture by the proposed method three times within the same day (repeatability).

  **Taken**   **Found**   **Standard deviation**                                                     
  ----------- ----------- ------------------------ ------- ------- -------- -------- -------- ------ ------
  30          48          30.8                     30.42   29.17   47.66    47.17    48.36    0.85   0.62
  50          80          50.25                    49.98   49.38   80.15    80.62    79.13    0.45   0.76
  65          104         63.97                    65.54   64.76   104.90   103.98   103.74   0.78   0.61
  80          128         80.14                    79.85   80.62   127.92   128.56   128.60   0.39   0.38

###### 

Results of quantitative analysis of amlodipine and valsartan in laboratory prepared mixture by the proposed method over three different days (reproducibility).

  **Taken**   **Found**   **Standard deviation**                                                     
  ----------- ----------- ------------------------ ------- ------- -------- -------- -------- ------ ------
  30          48          29.57                    30.43   29.00   49.31    47.86    48.52    0.72   0.73
  50          80          49.66                    49.13   50.51   80.39    81.45    79.72    0.67   0.87
  65          104         65.55                    66.05   64.74   105.37   103.87   104.68   0.66   0.75
  80          128         79.69                    79.22   80.85   129.10   127.98   128.66   0.84   0.56

###### 

Results of quantitative analysis of amlodipine and valsartan in exforge tablets by the proposed method.

  **Taken**   **Found**   **% recovery**                        
  ----------- ----------- ---------------- ------- ------------ --------------
  15          24          14.95            24.36   99.66        101.5
  40          64          39.58            63.57   98.95        99.33
  80          128         80.88            129.1   101.10       100.86
                          M ± SD                   99.9 ± 1.1   100.56 ± 1.1

###### 

Results for the application of the standard addition technique for the determination of amlodipine and valsartan in exforge tablets by the proposed method.

  **Taken from tablets (μg/ml)**   **Found of tablets**   **Added standard (μg/ml)**   **Found of added standard (μg/ml)**   **% recovery of added standard**                                           
  -------------------------------- ---------------------- ---------------------------- ------------------------------------- ---------------------------------- ----- -------- -------- --------------- ---------------
                                                          14.95                        24.36                                 25                                 40    25.21    39.58    100.85          98.94
  15                               24                                                                                        45                                 72    45.45    72.56    101.00          100.78
                                                                                                                             65                                 104   64.72    103.82   99.57           99.83
                                                          39.58                        63.57                                 15                                 24    15.08    24.13    100.53          100.54
  40                               64                                                                                        20                                 32    20.08    32.36    100.38          101.12
                                                                                                                             35                                 56    34.74    55.81    99.26           99.66
                                                                                                                                                                      M ± SD            100.27 ± 0.70   100.15 ± 0.81
